Macrobid is FDA-approved to treat urinary tract infections caused by two specific bacteria: Escherichia coli (E. coli) and Staphylococcus saprophyticus. These two organisms are responsible for the vast majority of uncomplicated bladder infections, which is the only condition Macrobid is indicated for. It does not treat kidney infections, bloodstream infections, or UTIs caused by other types of bacteria.
The Two Bacteria Macrobid Targets
E. coli is the dominant cause of bladder infections, responsible for roughly 80% of uncomplicated UTIs. It’s a gram-negative bacterium that normally lives in the intestines but can migrate to the urinary tract. Macrobid reaches high concentrations in urine, making it effective at killing E. coli right where the infection lives.
Staphylococcus saprophyticus is the second most common cause of UTIs in young, sexually active women, accounting for around 5 to 15% of cases. It’s a gram-positive skin bacterium that can colonize the urinary tract. While less well-known than E. coli, it’s a frequent enough culprit that the FDA specifically lists it on the Macrobid label.
Why Macrobid Only Works for Bladder Infections
Macrobid concentrates almost entirely in the urine rather than the bloodstream. Plasma levels never exceed 2 mg/L, while urine concentrations in people with normal kidney function typically stay above 50 mg/L throughout the day. That’s a roughly 25-fold difference. This means the drug reaches bacteria sitting in the bladder effectively but can’t reach infections that have spread to the kidneys or bloodstream.
This is why your prescriber won’t use Macrobid for a kidney infection (pyelonephritis), even if E. coli is the cause. The drug simply doesn’t get to kidney tissue in high enough concentrations to clear the infection. If you have symptoms like fever, back pain, or nausea alongside urinary symptoms, a different antibiotic is needed.
Bacteria Macrobid Does Not Cover
Several organisms that sometimes cause UTIs fall outside Macrobid’s effective range. Proteus species, Pseudomonas aeruginosa, Klebsiella, and Enterobacter are all common enough in urinary infections but are not reliably susceptible to nitrofurantoin. If a urine culture shows one of these organisms, your provider will switch to a different antibiotic.
This is one reason urine cultures matter. If you’re prescribed Macrobid empirically (before culture results come back) and your symptoms aren’t improving after two or three days, the infection may involve a bacterium that Macrobid can’t treat.
Resistance Rates Remain Low
One of Macrobid’s biggest advantages is that E. coli has been slow to develop resistance to it. A 2025 systematic review covering nearly 775,000 E. coli isolates from urinary infections worldwide found that only 6.9% were resistant to nitrofurantoin. That’s remarkably low compared to antibiotics like fluoroquinolones or trimethoprim-sulfamethoxazole, which have resistance rates exceeding 20 to 30% in many regions.
Resistance does vary by geography. Europe has the lowest prevalence at 1.7%, while Asia has the highest at 9.6%. In individual countries like India and Bangladesh, resistance climbs to 16 to 18%. In North America and Europe, Macrobid remains a highly reliable first-line choice for uncomplicated bladder infections, which is a major reason guidelines continue to recommend it.
Standard Treatment Course
The typical Macrobid regimen is one 100 mg capsule every 12 hours. For women with uncomplicated cystitis, the course runs 5 days. For men, guidelines generally recommend 7 days. Each capsule contains a blend of two forms of nitrofurantoin: 25 mg of a slower-dissolving macrocrystalline form and 75 mg of a monohydrate form that creates a gel matrix in the gut, releasing the drug gradually. This design reduces stomach irritation and keeps urine levels more consistent.
Taking Macrobid with food improves absorption and further reduces nausea, which is one of the more common side effects.
Kidney Function and Macrobid
Because Macrobid depends on the kidneys to concentrate it in urine, reduced kidney function is a real problem. If your kidneys can’t filter the drug efficiently, urine concentrations drop too low to kill bacteria, and the drug accumulates in the bloodstream where it can cause side effects without providing benefit.
The cutoff is an estimated glomerular filtration rate (eGFR) below 45. Below that threshold, Macrobid is generally not recommended. In select cases, a short 3 to 7 day course may still be used cautiously if the eGFR falls between 30 and 44, but only when the infecting bacterium is resistant to other options.
Use During Pregnancy
Macrobid is one of the antibiotics considered acceptable for treating UTIs during pregnancy, and the American College of Obstetricians and Gynecologists includes it as a recommended option. It can also be used as a daily suppressive dose (100 mg once daily) for pregnant individuals with recurrent UTIs, continuing through the remainder of pregnancy and up to 4 to 6 weeks postpartum. It is generally avoided near the end of pregnancy, at term, and during labor and delivery because of a theoretical risk of hemolytic anemia in the newborn.